- |||||||||| HH2710 / HaiHe Biopharma
Trial completion date, Trial primary completion date, Metastases: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors (clinicaltrials.gov) - Apr 19, 2022
P1/2, N=150, Recruiting,
N=150 --> 37 | Trial completion date: Dec 2024 --> Mar 2023 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Mar 2023; Sponsor business decision Trial completion date: Jul 2022 --> Dec 2024 | Trial primary completion date: Jun 2021 --> Dec 2023
- |||||||||| HH2710 / HaiHe Pharma
HH2710, a highly potent and selective erk1/2 inhibitor for the treatment of mapk mutant tumors (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_863;
In tumor xenograft models, HH2710 showed significant antitumor activity at the doses of 15, 30, and 60 mg/kg (twice per day, given orally) with the relative tumor volume at the endpoint (T/C value) of 51.0%, 18.1%, and 11.7% respectively, exhibiting improved efficacy over the front runner molecule in clinical development. Summary of pharmacokinetic parameters are listed in Table 1.The full in vitro and in vivo preclinical characterizations of HH2710 will be presented.Table 1, Pharmacokinetic parameters of HH2710 in mouse, SD rats and Beagle dogs
- |||||||||| HH2710 / HaiHe Biopharma
Enrollment open, Trial primary completion date, Metastases: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors (clinicaltrials.gov) - Mar 12, 2020
P1/2, N=150, Recruiting,
Summary of pharmacokinetic parameters are listed in Table 1.The full in vitro and in vivo preclinical characterizations of HH2710 will be presented.Table 1, Pharmacokinetic parameters of HH2710 in mouse, SD rats and Beagle dogs Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2020 --> Dec 2020
|
